RxDoctor Payments Data

Maria Haldar, MD

Internal Medicine · Milton, DENPI 1285689786

Payments from drug & device makers

$1,465in general payments, 2019–2025

Across 79 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$440
  • Novo Nordisk$248
  • Lilly USA, LLC$207
  • GSK$104
  • Boehringer Ingelheim$100
  • Johnson & Johnson$75
  • plus $291 from 10 others

What the payments were for

  • Food & beverage$1,44298%
  • Education$232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,465 in reported general payments places this provider in the 80th percentile of 477 internal medicine providers in Delaware.

See all internal medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$241,628
Medicare patients
645
Services billed
2,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$116,027
RybelsusSemaglutide46$83,188
EliquisApixaban81$77,510
JardianceEmpagliflozin70$73,845
TrulicityDulaglutide29$40,167
TradjentaLinagliptin28$29,853
JanuviaSitagliptin Phosphate22$22,307
FarxigaDapagliflozin Propanediol15$20,251
Breo ElliptaFluticasone/Vilanterol29$20,119
XareltoRivaroxaban14$19,569
MounjaroTirzepatide11$17,468
VascepaIcosapent Ethyl40$16,264
MyrbetriqMirabegron20$14,146
Atorvastatin Calcium909$12,709
TrintellixVortioxetine Hydrobromide12$11,751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$248$199,215114 claims
Boehringer IngelheimJardiance, Tradjenta$100$103,69898 claims
PfizerEliquis$26$77,51081 claims
Lilly USA, LLCTrulicity, Mounjaro$207$57,63540 claims
MerckJanuvia$25$22,30722 claims
AstraZenecaFarxiga$440$20,25115 claims
GSKBreo Ellipta$104$20,11929 claims
Johnson & JohnsonXarelto$75$19,56914 claims
Astellas Pharma US IncMyrbetriq$43$14,14620 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$29$11,75112 claims
AbbVieSynthroid$29$5,15185 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 477 internal medicine providers in Delaware.

Other internal medicine in Milton

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →